drugset / Trial / NCT05744128
CD8 Minibody Repeatability Study
NaSingle-groupOpen-labelDiagnostic
Summary
Zr-89 crefmirlimab berdoxam is a Zirconium-89 labelled minibody developed by ImaginAb for full body PET imaging of CD8+ cell distribution (CD8 ImmunoPET). The primary objective of this study is to assess the test-retest repeatability of CD8 immunoPET imaging in oncology patients with stable disease.
Timeline
- Start
- 2023-02-16
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
Outcome
Outcome not reported
Stopped (Business): “Strategic decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | crefmirlimab berdoxam | Diagnostic / imaging agent | 1.5 mg | Intravenous |
| Subject | crefmirlimab berdoxam | Diagnostic / imaging agent | 37 mbq | Intravenous |